Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Miyata, Yasuyoshi ^a   Watanabe, Shin ichi ^a   Kanetake, Hiroshi ^a   Sakai, Hideki ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

4N1K peptide; Angiogenesis; Matrixmetalloproteinase 9; Prognosis; Upper urinary tract; Urothelial cancer

Indexed keywords

GELATINASE B; LYSYLARGINYLPHENYLALANYLTYROSYLVALYLVALYLMETHIONYLTRYPTOPHYLLYSYLLYSINE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOTIC INDEX; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CELL PROLIFERATION; CELLULAR PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH VESSEL; LYMPH VESSEL DENSITY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MICROVESSEL DENSITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOSPONDIN 1; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84865326685     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-372     Document Type: Article

References (49)

1. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998, 52:594-601. 10.1016/S0090-4295(98)00295-7, 9763077.
2. Jeong IG, Kim SH, Jeon HG, Kim BK, Moon LC, Lee SE, Lee E. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 2009, 40:668-677. 10.1016/j.humpath.2008.10.010, 19157504.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995, 1:27-31. 10.1038/nm0195-27, 7584949.
4. Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006, 12:800-806. 10.1158/1078-0432.CCR-05-1284, 16467091.
5. Good DJ, Polverini PJ, Ranstinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment thrombospondin. Proc Natl Acad Sci USA 1990, 87:6624-6628. 10.1073/pnas.87.17.6624, 54589, 1697685.
6. Tolsma SS, Stack MS, Bouck N. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thorombospondin-1. Microvasc Res 1997, 54:13-26. 10.1006/mvre.1997.2015, 9245640.
7. Lawler J. thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002, 6:1-12. 10.1111/j.1582-4934.2002.tb00307.x, 12003665.
8. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008, 65:700-712. 10.1007/s00018-007-7486-z, 2752021, 18193162.
9. Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ, Wolf HK. Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchow Arch 2001, 438:116-120.
10. Nakao T, Kurita N, Komatsu M, Yoshikawa K, Iwata T, Utsunomiya T, Shimada M. Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol 2011, 16:145-152. 10.1007/s10147-010-0147-5, 21107877.
11. Miyata Y, Kanda S, Ohba K, et al. Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: association with clinicopathological features and prognosis. J Urol 2006, 176:348-353. 10.1016/S0022-5347(06)00520-9, 16753442.
12. Zhou M, He Y, Zu X, Zhang H, Zeng H, Qi L. Lymph vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder. BJU Int 2010, 107:1930-1935.
13. Albo D, Shinohara T, Tuszynski GO. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 2002, 108:51-60. 10.1006/jsre.2002.6452, 12443715.
14. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010, 183:1744-1750. 10.1016/j.juro.2010.01.018, 20299037.
15. Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of therombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001, 7:251-259. 10.1007/BF03032381, 11882904.
16. Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F, Kandemir B. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 2009, 205:854-857. 10.1016/j.prp.2009.07.015, 19762163.
17. Murphy G, Crabbe T. Gelatinases a and b. Mothods Enzymol 1995, 248:470-484.
18. Miyata Y, Kanda S, Nomata K, Hayashida Y, Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urology 2004, 63:602-608. 10.1016/j.urology.2003.09.035, 15028476.
19. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001, 98:12485-12490. 10.1073/pnas.171460498, 60080, 11606713.
20. Wei W, Kong B, Yang Q, Qu X. Hepatocyte growth factor enhances ovarian cancer cell invasion though down regulation of thrombospondin-1. Cancer Biol Ther 2010, 9:79-87.
21. Miyanaga K, Kato Y, Nakamura T, Matsumura M, Amaya H, Horiuchi T, Chiba Y, Tanaka K. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res 2002, 22:3941-3948.
22. Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Lausen T, Haukaas SA. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to agiogenesis, cell proliferation and cancer specific survival. J Urol 2009, 182:2144-2149. 10.1016/j.juro.2009.07.015, 19758660.
23. Yamashita Y, Sendo S, Hosokawa T, Tuszynski G, Kurohiji T, Beppu R, Shinohara T, Kinugasa T, Shirakusa T. Exogenous thrombospondin stimulates the proliferation of non-thrombospondin-producing cells. Int J Oncol 1998, 13:355-359.
24. Mateo V, Brown EJ, Biron G, et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemia cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood 2002, 100:2882-2890. 10.1182/blood-2001-12-0217, 12351399.
25. Manna PP, Frazier WA. CD47 meidates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 2004, 64:1026-1036. 10.1158/0008-5472.CAN-03-1708, 14871834.
26. Rath GM, Schneider C, Dedieu S, Rothhut B, Soula-Rothhut M, Ghoneim C, Sid CB, Morjani H, El Btaouri H, Martiny L. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta 2006, 1763:1125-1134. 10.1016/j.bbamcr.2006.08.001, 16962673.
27. Grossfeld GD, Ginsberg DA, Stein P, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alternations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997, 89:219-227. 10.1093/jnci/89.3.219, 9017002.
28. Goddard JC, Sutton CD, Jones JL, OByrne KJ, Kochelbergh RC. Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. Eur Urol 2002, 42:464-468. 10.1016/S0302-2838(02)00372-X, 12429155.
29. Pratt DA, Miller WR, Dawes J. Thrombospondin in malignant and non-malignant breast tissues. Eur J Cancer Clin Oncol 1989, 25:343-350. 10.1016/0277-5379(89)90028-X, 2522876.
30. Poon RT, Chung KK, Cheung ST, et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 2004, 10:4150-4157. 10.1158/1078-0432.CCR-03-0435, 15217952.
31. Firlej V, Mathieu JRR, Gilbert C, Lemonnier L, Nakhlé J, Gallou-Kabani C, Guarmit B, Morin A, Prevarskaya N, Delongchamps NB, Cabon F. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res 2011, 28:7649-7658.
32. Miyata Y, Koga S, Takehara K, Kanetatke H, Kanda S. Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 2003, 9:1734-1740.
33. Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 1996, 212:199-207.
34. Guo N-H, Krutzsch HC, Inman JK, Robert DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induced apoptosis of endothelial cells. Cancer Res 1997, 57:1735-1742.
35. Chandradekaran L, He CZ, Al-Barazi H, Krutzsch HC, Iruela-Arispe ML, Roberts DD. Cell contact-dependent activation of α2β1 intergrin modulated endothelial cell response to therombospondin-1. Mol Biol Cell 2000, 11:2885-2900. 14963, 10982388.
36. Kanda S, Shono T, Tomasini-Johansson B, Klint P, Saito Y. Role of thrombospondin-1 derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999, 252:262-272. 10.1006/excr.1999.4622, 10527617.
37. Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int 2012, in press.
38. Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2012, in press.
39. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003, 9:1741-1749.
40. Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000, 83:298-306. 10.1054/bjoc.2000.1268, 2374573, 10917542.
41. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994, 124:183-193. 10.1083/jcb.124.1.183, 2119887, 7507491.
42. Ioachim E, Michael MC, Salmas M, Damala K, Tsanou E, Michael MM, Malamou-Mitsi V, Stavropoulos NE. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 2006, 6:140. 10.1186/1471-2407-6-140, 1538616, 16732887.
43. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediator of angiogenesis in bladder cancer. Cancer Res 1998, 58:1298-1304.
44. Beecken WC, Engl T, Jonas D, Blaheta RA. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int J Mol Med 2009, 23:261-266.
45. Hawighorst T, Oura H, Streit M, Janes L, Nguyen L, Brown LF, Oliver G, Jackson DG, Detmar M. Thrombospondin-1 selectively inhbits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 2002, 21:7945-7956. 10.1038/sj.onc.1205956, 12439745.
46. Friedl P, Vischer P, Freyberg MA. The role of thrombospondin-1 in apoptosis. Cell Mol Life Sci 2002, 59:1347-1357. 10.1007/s00018-002-8512-9, 12363037.
47. Johansson U, Higginbottom K, Londei M. CD47 ligation induces a rapid caspase-independent apoptosis-like cell death in human monocytes and dendritic cells. Scand J Immunol 2004, 59:40-49. 10.1111/j.0300-9475.2004.01355.x, 14723620.
48. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by upregulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 1997, 235:403-412. 10.1006/excr.1997.3681, 9299165.
49. Xing C, Arai K, Park K-P, Lo EH. Induction of vascular endothelial growth factor and matrix metalloproteinase-9 via CD34 signaling in neurovascular cells. Neurochem Res 2010, 35:1092-1097. 10.1007/s11064-010-0159-6, 20364320.